COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #137
Source   PDF   Share   Tweet
See all 143 studies
10/2
Positive
Late treatment study
Nachega et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-1240 (Peer Reviewed)
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo
Retrospective 766 hospitalized patients in DRC showing mortality reduced from 29% to 11%, and improvement at 30 days increased from 65% to 84%.
Mortality cox regression adjusted hazard ratio aHR 0.26, p < 0.001
Risk of no improvement adjusted odds ratio aOR 0.28, p < 0.001
Using marginal structural model analysis these risks became:
Mortality MSM adjusted odds ratio aOR 0.65, p = 0.166
Risk of no improvement MSM adjusted odds ratio aOR = 0.65, p = 0.132
Median age 46, 630 treated with C Q+AZ.
death, ↓27.6%, p=0.17
no improvement, ↓25.8%, p=0.13
(odds ratio converted to relative risk)
Source   PDF   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.
Submit